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function [22] [23] [24] [25] . It is unclear whether blockade of the IL2R depletes Treg from the circulation, or modifies the CD25-expression [7] [8] [9] [10] [11] [12] [26] [27] [28] [29] .
Tregs can be divided into two subsets; natural Treg (nTreg) and induced Treg (iTreg). nTreg originates directly from the thymus and constitutively express FoxP3; the transcription factor that plays a critical role in their development and function. iTreg, which also express FoxP3, originates in the periphery by the differentiation of conventional T cells into Treg upon exposure to antigen in the presence of tolerogenic cytokines [30, 31] . After rATG induction therapy, it is likely, but still unknown, that in vivo iTreg will contribute to the repopulating Treg pool, as thymopoiesis, the generation of nTreg, decreases with age, and conversion of conventional T cells into iTreg may occur in the presence of donor antigen [16] [17] [18] [19] [20] 32] . Both subtypes of Treg have similar phenotypical and functional characteristics and consequently distinction between nTreg and iTreg by the standard markers, CD25, CD127 and FoxP3, is not possible. Recently, a specific DNA methylation pattern within the Treg-specific demethylated region (TSDR) of the FoxP3 gene has been identified that is highly demethylated in nTregs and methylated in iTregs [33] . Moreover, Helios, a member of the Ikaros transcription factor family, has come forward as a marker for nTregs [34] .
Here, we assessed how depleting and non-depleting induction therapies influence the mechanism of Treg homeostasis in kidney transplant patients. We determined Treg repopulation mechanisms, thymopoiesis, homeostatic proliferation and Treg conversion along with the analysis of whether nTreg or iTreg are present after induction therapy. These data were completed by functional analysis of the repopulated Treg.
M AT E R I A L S A N D M E T H O D S

Patients
Blood samples were obtained from 33 consecutive kidney transplant patients treated with either rATG (n = 15, Thymoglobuline ® , Genzyme/Sanofi, Paris, France) in a dose of 2 mg/ kg on Days 1, 2 and 3 after transplantation, or basiliximab (n = 18, Simulect ® , Novartis Pharma, Basel, Switzerland), a monoclonal antibody targeting the IL-2R, induction therapy in a dose of 20 mg on Days 0 and 4 after transplantation. Patients received triple maintenance therapy consisting of Tacrolimus (Prograf ® , Astellas Pharma Inc., Tokyo, Japan), mycophenolate mofetil (MMF; CellCept ® , Hoffmann-La Roche Ltd, Basel, Switzerland) and steroids, which were tapered after 3 months. There were no differences in patient age, gender, cytomegalovirus status and the occurrence of acute rejection episodes between the treatment groups (Table 1 ). In the rATG group, one patient was lost to follow-up due to graft loss after Month 6 and two patients in the basiliximab group because of rATG anti-rejection therapy at Month 1 and Month 6. The medical ethics committee of the Erasmus Medical Centre approved the study (MEC-2010-022). Blood [heparinized and ethylenediaminetetraacetic acid (EDTA)] was drawn before and at 1, 3, 6 and 12 months after transplantation. Heparinized Lithium blood was used to isolate peripheral blood mononuclear cells (PBMCs) by density gradient centrifugation using standard Ficoll-Paque procedures. Due to a shortage of material we were not able to analyse all parameters for each patient.
Flow cytometry
Absolute numbers of CD4+ T cells. Absolute counts of CD4 + T cells were determined in EDTA blood using BD MultiTest™ 6 color reagent and BD TruCount™ tubes (BD Biosciences, San Jose, CA), according to the manufacturer's instructions. In brief, EDTA blood (50 µL) was added to 20 µL MultiTest reagent in a BD TruCount tube containing a known number of fluorescent beads and incubated for 15 min in the dark at room temperature. After lysation with BD FACSLysing solution, samples were measured on a FACSCantoII™ (BD Bioscience) and analysed by FACSDiva™ software.
Percentage and absolute number of CD4+CD25+CD127− T cells. The percentage of CD4+CD25+CD127− T cells was determined in whole blood. Two hundred microlitres of blood was incubated with the following antibodies: CD3-PerCP, CD4-PB, CD25B-PE-Cy7 (BD Bioscience) and CD127-FITC (eBioscience, San Diego, CA); hereafter, cells were washed, red blood cells lysed, and fixated using lyse/Fix buffer (BD Bioscience). Next, samples were washed and measured on a FACSCantoII and analysed by BD FACSDiva Software. The absolute number of Tregs was determined by multiplying the percentage of CD4+CD25+CD127− T cells with the number of CD4+ T cells.
Phenotypical characterization of CD4+CD127−FoxP3+ regulatory T cells. PBMCs were thawed and extracellular stained with the following fluorochrome-conjugated antibodies: CD3-AmCyan, CD4-APC-H7 (BD Bioscience), CD31-PE (Biolegend), CD127-PeCy7 and CD45RO-PerCP-Cy5 (BD Bioscience). For intracellular staining with FoxP3-APC, Helios-PB (Biolegend) and Ki-67-FITC (BD Bioscience), the anti-human FoxP3 Staining Kit (eBioscience) was used. As negative control, Fluorescence Minus One controls were performed. A minimum of 100 events per population was set for analysis.
Cytokine production. PBMCs were stimulated in the presence of Brefeldin A (Golgiplug, BD Bioscience) with phorbol myristate acetate (50 ng/mL, Sigma-Aldrich, St. Louis, MO) and Ionomycine (1 µg/mL, Sigma-Aldrich) for 4 h. For determining the production of intracellular cytokines, cells were stained with FoxP3-APC, IL-10-AlexaFluor488 (Biolegend) and IFNγ-PE (BD Bioscience) using the anti-human FoxP3 Staining Kit (eBioscience). Unstimulated cells were used as baseline samples.
Suppression assay
PBMCs were stained with CD3-AmCyan, CD4-PB, CD25-PeCy7, CD127-PE, 7AAD (BD Bioscience) and cell-sorted for Treg; CD3+CD4+CD25+CD127− and Teff; CD4+CD25 −CD127+, using the BD FACSAriaII (BD Bioscience) cell sorter. Purity of sorted Tregs and Teff was >95%. FACSsorted Treg were co-cultured in a ratio of 1:5 (Treg:Teff ) in a mixed lymphocyte reaction (MLR) consisting of Teff cells stimulated in a 1:1 ratio with γ-irradiated (40 Gy) donor or human leucocyte antigen mismatched (2-2-2) third party stimulator cells. After 7 days' incubation, proliferation was measured as counts per minute (CPM), using Wallac1450 MicroBeta TriLux (PerkinElmer, Groningen, The Netherlands), after 16 h incubation with [
3 H]-thymidine incorporation (0.5 mCi/well; PerkinElmer) before harvesting (as described by Hendrikx et al. [36] ). Treg function was defined as Treg capable of inhibiting proliferation of donor or third party antigen stimulated Teff cells.
Methylation status of the FOXP3 gene The methylation status of the TSDR of the FoxP3 gene was determined in FACSsorted CD3+CD4+CD25+CD127−Treg. Cell pellets were digested with proteinase K and treated with bisulfite using the EZ DNA Methylation-Direct™ Kit (Zymo Research, Irvine, CA). During bisulfite treatment unmethylated cytosines were converted into uracils while methylated cytosines remain unmodified. Hereafter, the TSDR of the FoxP3 gene was amplified by quantitative real-time PCR using the StepOnePlus™ Real-Time PCR System and the TaqMan ® Genotyping Master Mix (Applied Biosystems, Foster City, CA). Methylation-specific and demethylation-specific amplification primers and probes were chosen as described by Wieczorek et al. [37] . The percentage of Treg with a demethylated TSDR was calculated using the ratio of amplified demethylated TSDR copies and the sum of amplified methylated and unmethylated TSDR copies. In female patients, the percentage of demethylated TSDR was multiplied by two to correct for the X-linked nature of the FoxP3 gene.
Statistical analysis
Statistical analyses were performed using Graphpad Prism version 5.01. For comparisons within multiple groups the Kruskal-Wallis with Dunn's multiple comparison test, for comparison between time points or groups, the MannWhitney U-test was used. Analysis of contingency tables was conducted using Fisher's exact test. For relations between parameters, a linear regression model was used and Spearman Rho correlation coefficient (r s ) was calculated. P values ≤ 0.05 were considered statistically significant.
R E S U LT S
CD4+ T cells and CD4+CD25+CD127− T cells
The absolute number of CD4+ T cells and CD4+CD25 +CD127− T cells were determined in the blood of kidney transplant patients treated with rATG or basiliximab induction therapy ( Figure 1A -C). As basiliximab hinders the detection of CD25 by certain antibodies, we used clone MA251 detecting CD25epitope B, which does not interfere with basiliximab [38] . At 1 month after rATG induction we observed a significant decrease in the absolute number of both CD4+ T cells and CD4+CD25+CD127− T cells (P < 0.001 versus pretransplantation, Figure 1B ). Thereafter the number of CD4+ T cells and CD4+CD25+CD127− T cells slowly increased but did not reach pre-transplant levels ( Figure 1B ). Basiliximab treated patients showed no differences in the absolute number of CD4+ T cells while the absolute numbers of CD4+CD25 +CD127− T cells decreased at 1 and 3 months (P < 0.01, Figure 1C ). At all post-transplant time points, basiliximab treated patients had higher absolute numbers of CD4+ and CD4+CD25 +CD127− T cells ( Figure 1B and C, P < 0.001). Figure 1D depicts the proportion of CD4+CD25+CD127− T cells within the CD4+ T-cell population; at 3 and 6 months after rATG induction therapy the percentage of Treg was higher than before transplantation ( Figure 1D , P < 0.05). In contrast, the proportion of Treg after basiliximab induction therapy was significantly lower for the whole study period (P < 0.01). At Month 3 and Month 6, rATG treated patients had a higher percentage of CD4+CD25+CD127− T cells than basiliximab treated patients ( Figure 1D , P < 0.01).
Regulatory T cells after induction therapy and repopulation mechanisms
In addition, Tregs were characterized for the Treg marker FoxP3 and the memory marker CD45RO (Figure 2A ). At Month 6, higher percentages of CD4+CD127−FoxP3+ Treg were observed in the rATG group and lower percentages in the basiliximab group (P < 0.05, Figure 2B ) than in patients before transplantation. In both patient groups, at all time points, the majority of CD127−FoxP3+ Treg expressed CD45RO, though after rATG treatment the CD45RO expression remained constant, while we found a low percentage of CD4+CD45RO +CD127−FoxP3+ Treg, 6 months after basiliximab therapy (P < 0.05, Figure 2C) .
Thymopoiesis, the formation of CD31 expressing RTEs, is an age related process; the presence of CD31+ naïve T cells decreases with age [39, 40] . This inverse correlation was also present for CD31+CD45RO− Treg and age, before and after transplantation ( Figure 3B ; r = −0.6798, P = 0.04 and r = −0.5671, P < 0.001). Consequently, we used CD31 as a marker for RTE-Treg. No differences in the percentage of RTE-Treg were observed ( Figure 3C ). Homeostatic proliferation of CD4 +CD127−FoxP3+ Treg was measured by the expression of Ki-67, an antigen present during the G1-M phase of the cell cycle ( Figure 3D ) [41] . Patients at 1 month after rATG induction therapy had higher percentages of Ki-67+ Tregs than patients before transplantation ( Figure 3E , P < 0.001). At 1 month after basiliximab therapy, patients had low percentages of Ki-67+ Tregs. Surprisingly, at 6 months after basiliximab, the percentage of Ki-67+ Tregs was higher than in patients before transplantation ( Figure 3E , P < 0.05). A comparable expression pattern of Ki-67 was seen by CD45RO+, memory Treg ( Figure 3F) , while for the CD45RO− naïve Treg, only at 6 months after basiliximab therapy, were high percentages of Ki-67+CD4+CD45RO−CD127−FoxP3+ Treg observed (P < 0.05, Figure 3G ). 
Origin of repopulated Tregs
To determine the origin of Tregs present after induction therapy we studied Helios expression by Ki-67+CD4+ CD45RO+CD127−FoxP3+ Treg ( Figure 4A ) and the FoxP3 demethylation profile of cell-sorted CD4+CD25+CD127− Treg. At 1 and 12 months after rATG therapy, low percentages of Helios+ Ki-67+CD4+CD45RO+CD127−Foxp3+ Treg were measured ( Figure 4B , P < 0.05), suggestive for the generation of iTreg, while after basiliximab therapy the percentage of Helios+ Ki-67+CD4+CD45RO+CD127−Foxp3+ Treg was comparable ( Figure 4B ). The relation between the expression of Helios and Ki67 in CD45RO+Treg is shown in Figure 4C . From a subset of patients, we had samples at 6-12 months after induction therapy available to study the methylation of TSDR in the FoxP3 gene, where a demethylated TSDR represents an nTreg. Figure 4D shows that after rATG induction therapy, the percentage of cells with a demethylated TSDR in the FOXP3 gene was lower than after basiliximab therapy, suggestive for the induction of iTreg after rATG therapy (P < 0.05). Treg in patients before and in rATG and basiliximab treated patients 1, 6 or 12 months after transplantation. Due to a shortage of material we were not able to measure all parameters for all patients. Data are shown as median ± IQR. *P < 0.05, **P < 0.01, ***P < 0.001.
O R I G I N A L A R T I C L E S
H o m e o s t a s i s a n d f u n c t i o n o f T r e g a f t e r i n d u c t i o n t h e r a p y The percentage of Ki-67+ CD4+CD45RO−CD127−FoxP3+ Treg in patients before transplantation and in patients at 1, 6 or 12 months after rATG or basiliximab induction therapy. Due to a shortage of material we were not able to measure all parameters for all patients. Data are shown as median ± IQR. *P < 0.05, **P < 0.01, ***P < 0.001.
Functional capacities of regulatory T cells
We next studied the functional capacities of repopulated Treg. There was no difference in the IFNγ production capacity by Treg in patients before and after induction therapy ( Figure 5A and B). For the IL-10 production capacity of Tregs, we observed a different pattern. At 1 and 12 months after rATG therapy, Tregs had a higher IL-10 production capacity than Tregs from patients before transplantation, while only at Month 1 after basiliximab a higher IL-10 production was observed ( Figure 5C ).
The suppressive capacity of the repopulated Tregs was studied by the classical MLR suppression assay. Teff cells from patients before and at 6-12 months after transplantation were stimulated with donor or third party antigen, in the absence or presence of FACSsorted CD4+CD25+CD127− Treg (Treg:Teff = 1:5). Before transplantation, there was no difference in the capacity of Treg to inhibit donor or third party stimulated proliferation of Teff cells; respectively, 6 and 5 out of 11 patients inhibited the proliferative response to donor and third party stimulated cells ( Figure 5D ). After rATG therapy, Treg from four out of five patients inhibited donor stimulated proliferation but could not control proliferation of third party stimulated Teff cells ( Figure 5D and E, P < 0.05). After basiliximab therapy, Tregs comparably inhibited donor and third party stimulated Teff cells in both situations Treg from 4 out 7 patients inhibited Teff proliferation. Due to a large variation in the suppressive capacity of Treg, no statistical differences were found in the percentage of inhibition ( Figure 5E ).
Rejectors versus non-rejectors
We observed no difference in the occurrence of acute rejection episodes (biopsy proven and defined according to the Banff 07 classification [35] ) between rATG and basiliximab treated patients (Table 1) . At baseline, no differences were found between rejectors and non-rejectors. No associations were found between rejection and the studied parameters.
D I S C U S S I O N
To define the impact of induction therapy on the immunesuppressive counter mechanism, we here studied different Treg features after rATG and basiliximab induction therapy. In absolute numbers, rATG therapy depleted CD4+CD25+ CD127− T cells with an incomplete recovery at 12 months. During repopulation, particularly the first 6 months, high percentages of CD4+CD25+CD127− T cells and CD4+CD127− FoxP3+ T cells were observed. Basiliximab treated patients showed decreased absolute numbers of CD4+CD25+CD127− T cells, which was accompanied by a decreased percentage of CD4+CD25+CD127− T cells, for at least 1 year. For CD4+ CD127−FoxP3+ T cells a different observation was made; only at 6 months low percentages of CD4+CD127−FoxP3 T cells were found. After both induction therapies, the Treg pool reconstituted by homeostatic proliferation of Treg with the memory phenotype. However, rATG treated patients had increased percentages of Helios-iTreg, with a demethylated FoxP3 gene, while after basiliximab no changes in Treg phenotype were found. After T-cell depletion, repopulated Treg were able to inhibit donor, but not third party antigen, stimulated Teff cells.
After T-cell depletion, in adult patients, homeostatic proliferation largely contributes to T-cell reconstitution as thymopoiesis is inversely correlated with age [5, 14, 15, [42] [43] [44] . However, in patients suffering from T-cell depletion due to chemotherapy, human immunodeficiency virus infection or rATG therapy, increased thymopoiesis has been described [5, [45] [46] [47] . We could not confirm these data. An explanation for these findings may be the use of CD31 as RTE-marker, as CD31+ naïve CD4+ T cells in human adults can also be formed by peripheral proliferation [48] . However, as shown earlier by our group, the percentages of Ki-67+CD4+CD31+ CD45RO− T cells after rATG therapy are small. Therefore, we speculate that the contribution of proliferating CD31+ naïve Treg is limited. Furthermore, differences in timing [5] or a difference in the extent of end stage renal disease and consequently the duration of uraemia, which influences thymicoutput [49] [50] [51] , may underlie the different findings.
As high percentages of memory T cells are found in the circulation after T-cell depletion therapy, Treg repopulation is thought to be the result of homeostatic proliferation of memory FoxP3+ T cells [5, 41, 44] . In addition, in vitro experiments showed that rATG converts CD25− effector T cells into CD25+FoxP3+ suppressor cells [8, 16, 18, 20] . However, Broady et al. [52] reported that these cells were just activated FoxP3+ cells. By analysing the proliferation marker Ki-67, we found, shortly after rATG therapy, indeed high percentages of especially Ki-67+CD45RO+, memory, Treg. In addition, our findings of the nTreg-marker Helios and the methylation status of the FoxP3 gene, as well as the suppressive capacities of Treg, showed that rATG induces iTreg in vivo and that these cells were not activated cells. Though, the Treg repopulation mechanisms do not completely restore the Tregpool (Figure 1 ). Phenomena like T-cell exhaustion and deprivation of the cytokine milieu may explain this incomplete recovery [15, 53] .
After basiliximab therapy, low numbers of CD4+CD25 +CD127− T cells were also observed. This cannot be explained by competition between basiliximab and anti-CD25 antibodies [38] . Some reports state that after basiliximab therapy, CD25+ and CD25+FoxP3+ T cells are depleted, while others state that functional, suppressive, FoxP3+ cells remain in the circulation, albeit with low CD25 expression, caused by modulation or shedding of the CD25 molecule [7, 9, 12, [27] [28] [29] . Our findings point to an effect on the CD25 molecule as well, as at 1 month after basiliximab therapy low percentages of CD4+CD25+CD127− T cells, but not of CD4+CD127−FoxP3+ T cells, were found. At 6 months after basiliximab, CD4+CD127−FoxP3+ T cells were affected. This is most likely the net-result of the given immunosuppressive medication, or late apoptotic events triggered by the earlier blockade of the IL2-IL2R pathway.
To determinate the origin of Ki-67+Treg, we analysed the expression of Helios, a marker for nTreg [34] . In the rATG group, relatively low percentages of Helios+ proliferating Treg were measured, suggesting a contribution of Helios-iTreg. After basiliximab therapy, we did not observe this phenomenon. Currently, there is some debate about the value of Helios as a marker for nTreg as recently published studies showed that this marker is also up regulated by Treg and nonTreg after stimulation [54] . In addition, it was found that Helios− and Helios+ Treg, co-exist in the nTreg pool [55] [56] [57] [58] . Therefore, we complemented our Helios data with the analysis of the demethylation status of the FoxP3 gene. After rATG therapy, the percentage of CD4+CD25+CD127− Tregs with a demethylated TSDR of the Foxp3 gene, i.e. nTreg, decreased confirming our Helios findings.
Among the various mechanisms by which Treg suppress immune responses, the immunoregulatory cytokine IL10 plays a prominent role [13] . After rATG and basiliximab therapy, the IL10 production capacity was higher than in patients before transplantation. When we studied the suppressive capacities of Treg, differences between groups were observed. After rATG therapy the FACSsorted CD4+CD25+CD127− Tregs suppressed donor antigen-specific proliferation of Teff cells, whereas proliferation in response to third party antigen was insufficiently inhibited. Tregs of basiliximab treated patients comparably inhibited the proliferation of donor and third party stimulated Teff cells. This difference in suppression between the two treatment groups might be related to the difference found in Helios expression and the demethylation status of the FoxP3 gene; the relative increase in iTreg favoured by rATG treatment. However, as in our study no significant differences were found in the percentage of inhibition between treatment groups and between donor and third party stimulated effector T cells, we can only speculate that these newly formed iTreg, after rATG therapy, have donor-specific immunoregulatory properties.
In conclusion, in kidney transplant patients, repopulation of Treg after rATG and basiliximab therapy is the result of homeostatic proliferation and not of thymopoiesis. These repopulated Treg were functional after both induction strategies; however, only after rATG therapy, were increased proportions of Helios − methylated FoxP3 Treg found.
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